{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T05:59:48Z","timestamp":1793771988973,"version":"4.6.1"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:00:00Z","timestamp":1712880000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.leukres.2024.107500","type":"journal-article","created":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T13:45:29Z","timestamp":1713188729000},"page":"107500","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Poor prognosis of SRSF2 gene mutations in patients treated with VEN-AZA for newly diagnosed acute myeloid leukemia"],"prefix":"10.1016","volume":"141","author":[{"given":"Guillaume","family":"Berton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bochra","family":"Sedaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwann","family":"Collomb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Benachour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Loschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilal","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colombe","family":"Saillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosr","family":"Hicheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Rouzaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio","family":"Maisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinand","family":"Villetard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyne D.'Incan","family":"Corda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Charbonnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Rey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Anne","family":"Hospital","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Ittel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman","family":"Abbou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphaelle","family":"Fanciullino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9reng\u00e8re","family":"Dadone-Montaudi\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Vey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffroy","family":"Venton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Cluzeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Alary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Garciaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.leukres.2024.107500_bib1","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med"},{"issue":"1","key":"10.1016\/j.leukres.2024.107500_bib2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.leukres.2024.107500_bib3","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1016\/S2352-3026(20)30210-6","article-title":"10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial","volume":"7","author":"DiNardo","year":"2020","journal-title":"Lancet Haematol."},{"issue":"Supplement 1","key":"10.1016\/j.leukres.2024.107500_bib4","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-187331","article-title":"Real World Use of Azacitidine and Venetoclax in Acute Myeloid Leukemia in Frontline and Relapse\/Refractory Settings: A Multicentric Study from French Auraml Group","volume":"142","author":"Gross","year":"2023","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2024.107500_bib5","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/bloodadvances.2020003734","article-title":"Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed\/refractory AML","volume":"5","author":"Stahl","year":"2021","journal-title":"Blood Adv."},{"issue":"8","key":"10.1016\/j.leukres.2024.107500_bib6","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.3390\/cancers14082025","article-title":"Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients","volume":"14","author":"Garciaz","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.leukres.2024.107500_bib7","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1182\/blood-2022-169509","article-title":"ELN Risk Stratification is not predictive of outcomes for treatment-na\u00efve patients with acute myeloid leukemia treated with venetoclax and azacitidine","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.leukres.2024.107500_bib8","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1158\/1078-0432.CCR-22-1183","article-title":"Outcomes in Patients with poor-risk cytogenetics with or without TP53 mutations treated with venetoclax and azacitidine","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin. Cancer Res"},{"issue":"Supplement 1","key":"10.1016\/j.leukres.2024.107500_bib9","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-173909","article-title":"Genetic Mutation and outcome of venetoclax-based therapy in newly diagnosed AML in the real world: hokkaido leukemia net study","volume":"142","author":"Miyashita","year":"2023","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.leukres.2024.107500_bib10","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic Classification and Prognosis in Acute Myeloid Leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med"},{"issue":"10","key":"10.1016\/j.leukres.2024.107500_bib11","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.3324\/haematol.2020.252825","article-title":"Clinical significance of chromatin-spliceosome acute myeloid leukemia: a report from the Northern Italy Leukemia Group (NILG) randomized trial 02\/06","volume":"106","author":"Chiara Caprioli","year":"2020","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.leukres.2024.107500_bib12","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/bloodadvances.2020004173","article-title":"Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax","volume":"5","author":"Lachowiez","year":"2021","journal-title":"Blood Adv."},{"issue":"19","key":"10.1016\/j.leukres.2024.107500_bib13","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1182\/blood.2023020649","article-title":"Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia","volume":"142","author":"Senapati","year":"2023","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.leukres.2024.107500_bib14","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1038\/s41375-023-01999-6","article-title":"Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients","volume":"37","author":"Jahn","year":"2023","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.leukres.2024.107500_bib15","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2024.107500_bib16","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1038\/s41467-018-06063-x","article-title":"Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia","volume":"9","author":"Shiozawa","year":"2018","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.leukres.2024.107500_bib17","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nm.4493","article-title":"H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers","volume":"24","author":"Seiler","year":"2018","journal-title":"Nat. Med"},{"issue":"8","key":"10.1016\/j.leukres.2024.107500_bib18","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/s43018-020-0103-x","article-title":"Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia","volume":"1","author":"Zhang","year":"2020","journal-title":"Nat. Cancer"},{"issue":"1","key":"10.1016\/j.leukres.2024.107500_bib19","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ccell.2022.12.002","article-title":"Modulation of RNA splicing enhances response to BCL2 inhibition in leukemia","volume":"41","author":"Wang","year":"2023","journal-title":"Cancer Cell"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212624000663?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212624000663?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T12:25:00Z","timestamp":1716899100000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212624000663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":19,"alternative-id":["S0145212624000663"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107500","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Poor prognosis of SRSF2 gene mutations in patients treated with VEN-AZA for newly diagnosed acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107500","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107500"}}